Skip to main content
Two people smiling and pointing at camera

A new way forward

PEGASUS (NCT03533257) was a Phase 2a, randomized, placebo-controlled trial in 95 participants in the U.S. evaluating safety, tolerability, neurobiological activity, and preliminary clinical efficacy of AMX0035 in a broad range of participants with early dementia or late mild cognitive impairment due to Alzheimer’s disease.

Trial update

The PEGASUS trial has completed and top line results were presented in November 2021. Read more details in this press release (opens new window).

AMX0035

Zoomed in microscopic view of motor neuron

AMX0035

We are currently exploring the potential of our investigational therapy, AMX0035 (sodium phenylbutyrate/taurursodiol), for the treatment of ALS, Alzheimer’s disease, and Wolfram syndrome. Our aim is to expand upon this innovation to address other neurodegenerative diseases.

Our commitment

At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We dedicate every passing minute to developing potential therapies that will give them more quality time with friends, family, and loved ones.

Clinical trials

Our innovative approach to developing  transformative therapeutics has far-reaching potential to  improve the management of multiple neurodegenerative  diseases. Learn more about our clinical trials. 

Latest News